DEF 14A: Tenon Medical Seeks Shareholder Approval for Warrant Exercise and Expanded Equity Plan Ahead of 2025 Annual Meeting

Tenon Medical, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include the election of directors, approval of new warrants from a recent inducement transaction, and a significant increase in the company's equity incentive plan share reserve.

Summary

• Tenon Medical, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Wednesday, July 23, 2025, at 10:30 a.m. Pacific Time.
• Stockholders of record as of June 6, 2025, are entitled to vote.
• The company is seeking approval for the exercisability of Series C-1 Warrants (up to 2,445,700 shares) and Series C-2 Warrants (up to 1,222,850 shares) at an exercise price of $1.25 per share, issued as part of a March 11, 2025 inducement transaction where existing warrants with a $4.28 exercise price were exercised for cash.
• Shareholder approval is required for the new warrants to become exercisable due to Nasdaq listing rules concerning private issuances exceeding a 20% threshold at a discount to market price.
• The company proposes to amend its 2022 Equity Incentive Plan to increase the shares reserved for issuance from 189,870 to 1,328,365 shares.
• The 2022 Plan's evergreen provision is also proposed to be amended, allowing for an annual automatic increase of shares on January 1, starting in 2026, to the greater of 4% of outstanding common stock or a number that brings the total reserved shares to 15% of outstanding common stock, or a lesser number as determined by the administrator.
• Seven directors are nominated for election to serve until the 2026 Annual Meeting: Steven Foster, Richard Ginn, Ivan Howard, Richard Ferrari, Kristine Jacques, Robert Weigle, and Stephen Hochschuler, M.D.
• Stockholders will also vote to ratify the appointment of Haskell and White, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• A proposal to adjourn the Annual Meeting, if necessary, to solicit additional proxies for the other proposals is also on the agenda.
• As of the Record Date (June 6, 2025), Tenon Medical had 7,589,970 shares of common stock, 256,968 shares of Series A Preferred Stock, and 86,454 shares of Series B Preferred Stock outstanding.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, which inherently presents proposals in a positive light from the company's perspective, emphasizing benefits like talent retention and future fundraising. However, the significant potential dilution from the warrant inducement and the expanded equity plan introduces a notable negative aspect for existing shareholders, balancing the overall sentiment towards neutral to slightly positive.

Positives

• The warrant exercise inducement transaction on March 11, 2025, allowed the company to raise funds by inducing a holder to exercise existing warrants for cash, which is presented as enhancing future fundraising ability.
• The proposed amendment to the 2022 Equity Incentive Plan aims to ensure the company can continue to attract, retain, and incentivize qualified employees, consultants, and directors in a competitive labor market.
• The Board of Directors recommends a 'FOR' vote on all proposals, indicating management's belief that these actions are in the best interests of the company and its stockholders.
• The company maintains a majority of independent directors on its Board, aligning with good corporate governance practices.

Negatives

• The warrant exercise inducement transaction involved a significant reduction in the exercise price from $4.28 to $1.25 per share for 2,445,700 existing warrants, potentially indicating a need for immediate capital or a response to market conditions.
• The issuance of new Series C-1 and C-2 Warrants, totaling up to 3,668,550 shares, at an exercise price of $1.25 per share, represents potential future dilution for existing shareholders.
• The proposed increase in the 2022 Equity Incentive Plan share reserve from 189,870 to 1,328,365 shares, and the expanded evergreen provision, could lead to substantial future dilution from equity compensation awards.

Risks

• If stockholder approval for the exercisability of the New Warrants is not obtained, the warrants will remain unexercisable, potentially impacting the company's ability to complete the inducement transaction and raise funds.
• The significant increase in shares reserved under the 2022 Equity Incentive Plan and the expanded evergreen provision could lead to substantial dilution of existing shareholder value if a large number of equity awards are granted and exercised.
• The company's ability to attract and retain talent may be hindered if the proposed amendments to the 2022 Equity Incentive Plan are not approved, potentially impacting future growth and operational stability.

Future Outlook

The document indicates the company's intention to continue attracting, retaining, and incentivizing qualified employees, consultants, and directors through an expanded equity compensation plan. It also highlights the company's efforts to enhance its ability to raise funds in the future through the approval of the warrant exercise inducement transaction.

Management Comments

• Steven Foster, Director, Chief Executive Officer and President: "Thank you for your on-going support of Tenon Medical, Inc."
• Steven Foster, Director, Chief Executive Officer and President: "I urge you to please complete, date and return the proxy card in the enclosed envelope, vote your shares electronically or vote by telephone using the information provided in the attached Proxy Statement prior to the Annual Meeting date. The vote of each stockholder is very important."
• Richard Ferrari, Executive Chairman of the Board: "The Board has determined that each proposal listed above is in the best interests of the Company and its stockholders and has approved each proposal. The Board recommends a vote FOR the Election of each director nominee (Proposal 1), FOR the Warrant Approval Proposal (Proposal 2), FOR the approval of the 2022 Plan Amendment Proposal (Proposal 3), FOR the Auditor Appointment Proposal (Proposal 4) and FOR the Adjournment Proposal (Proposal 5)."

Industry Context

This DEF 14A filing is a standard corporate governance document for a publicly traded medical device company. The proposed increase in the equity incentive plan share reserve is a common practice for growth-oriented companies in competitive sectors like medical devices, aiming to attract and retain talent. The warrant inducement transaction suggests a strategic move to raise capital, which is not uncommon for companies in the medical device industry that may require significant funding for R&D, commercialization, or operational needs.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• To the best of the company's knowledge, none of its directors or executive officers have been involved in any legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K during the past ten years.

Related Party Transactions

• The Ferrari Consulting Agreement, dated May 7, 2021, with Richard Ferrari (Executive Chairman), provides compensation of $22,500 per month starting September 1, 2021.
• Under the Ferrari Consulting Agreement, Mr. Ferrari received a bonus of $350,000 upon the closing of the company's initial public offering in April 2022.
• In May 2022, Mr. Ferrari was granted RSUs with a grant date fair value of $2,427,020, vesting over three years.
• Compensation paid to Mr. Ferrari totaled $270,000 in fiscal year 2024 and $247,500 in fiscal year 2023.

Stakeholder Impact

• **Shareholders**: Potential dilution from the exercisability of new warrants and the significant increase in the equity incentive plan share reserve. Voting on key corporate governance matters, including director elections and auditor ratification.
• **Employees**: The proposed increase in the 2022 Equity Incentive Plan share reserve is intended to enhance the company's ability to attract, retain, and incentivize qualified employees, potentially benefiting employee morale and recruitment efforts.
• **Management**: Compensation details for executive officers and directors are disclosed, and the proposed equity plan amendments directly impact their incentive structures.
• **Creditors/Investors**: The warrant exercise inducement transaction and the proposed equity plan amendments could impact the company's capital structure and future fundraising capacity, which is relevant for creditors and potential investors.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on July 23, 2025.
• Company management to report on performance and respond to stockholder questions after the Annual Meeting.
• Company to announce final voting results on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting.
• If approved, the New Warrants will become exercisable for five years (Series C-1) and three years (Series C-2) from the date stockholder approval is obtained.
• If approved, the amended 2022 Equity Incentive Plan will increase its share reserve, with annual automatic increases beginning January 1, 2026.

Key Dates

Keywords

SEC filing, Proxy Statement, Annual Meeting, Tenon Medical, Corporate Governance, Warrants, Equity Incentive Plan, Shareholder Vote, Dilution, Executive Compensation, Board of Directors, Auditor Ratification, Medical Device, Nasdaq Listing Rules